Key Details
Price
$550.00Annual Revenue
$1.23 BAnnual EPS
-$5.16Annual ROE
-8.54%Beta
-Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
VYVDURA ® has received approval for self-injection at home in Japan for the treatment of generalized myasthenia gravis and CIDP.
On November 26, 2024, in Amsterdam, the Netherlands, argenx (Euronext & Nasdaq: ARGX), a worldwide immunology company focused on helping those with serious autoimmune diseases, shared that its management team will take part in several investor conferences in December.
Phase 2 data has shown that efgartigimod SC is a promising treatment for myositis, and enrollment will proceed to Phase 3 for all three subtypes (IMNM, ASyS, DM) in the ALKIVIA study. This treatment could be the first targeted option for myositis patients who have few alternatives. Argenx SE, a global immunology company, announced this decision after reviewing the initial results from the Phase 2 study.
Argenx (ARGX) shares have begun to rise and could keep increasing soon, based on positive changes in earnings forecasts.
This is a comparison of how argenx SE (ARGX) and Novartis (NVS) have done in relation to their industry this year.
On November 5, 2024, in Amsterdam, the Netherlands, argenx (Euronext & Nasdaq: ARGX), a worldwide immunology company focused on enhancing the lives of those with serious autoimmune diseases, shared that its management team will take part in several investor conferences this November.
Argentx SE (NASDAQ:ARGX) will hold its Q3 2024 Earnings Conference Call on October 31, 2024, at 8:30 AM ET. The call will feature company representatives including Beth DelGiacco, Tim Van Hauwermeiren, Karl Gubitz, and Karen Massey, along with various participants from financial institutions like Wells Fargo, Bank of America, and JPMorgan. The operator will begin the call by welcoming everyone.
On October 24, 2024, in Amsterdam, the Netherlands, argenx (Euronext & Nasdaq: ARGX), a worldwide immunology firm focused on helping those with serious autoimmune diseases, announced that it will hold a conference call and audio webcast on Thursday, October 31, 2024, at 1:30 PM CET (8:30 AM ET). The purpose of this event is to discuss its financial results for the third quarter of 2024 and share a business update.
Long-term and real-world studies of VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) show how quickly the treatment works, how effective it is, and how long the effects last.
As we enter a strong fourth quarter, it's wise to invest in stocks that show good earnings growth, like Argenx, Alphatec Holdings, and Olin Corporation.
FAQ
- What is the primary business of argenx SE?
- What is the ticker symbol for argenx SE?
- Does argenx SE pay dividends?
- What sector is argenx SE in?
- What industry is argenx SE in?
- What country is argenx SE based in?
- When did argenx SE go public?
- Is argenx SE in the S&P 500?
- Is argenx SE in the NASDAQ 100?
- Is argenx SE in the Dow Jones?
- When was argenx SE's last earnings report?
- When does argenx SE report earnings?
- Should I buy argenx SE stock now?